

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 March 2019 (28.03.2019)



(10) International Publication Number
WO 2019/057792 A1

- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61K 39/00* (2006.01)
- (21) **International Application Number:**
PCT/EP2018/075388
- (22) **International Filing Date:**
19 September 2018 (19.09.2018)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
17191974.9 19 September 2017 (19.09.2017) EP
- (71) **Applicant:** **MAB DISCOVERY GMBH** [DE/DE];
Forstenrieder Straße 8-14, 82061 Neuried (DE).
- (72) **Inventors:** **FISCHER, Stephan**; Alpspitzstr. 1, 82362
Weilheim (DE). **BECKMANN, Karsten**; Astenweg 37,
85591 Vaterstetten (DE).
- (74) **Agent:** **WEICKMANN & WEICKMANN PARTMBB** et
al.; Postfach 860 820, 81635 München (DE).

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

- (54) **Title:** AGONISTIC CD40 ANTIBODIES

Fig.1:

Antibody	Cell binding EC50 [ng/ml]
MAB-16-0262	6,3
MAB-16-0346	49,5
MAB-16-0451	8,9
MAB-16-0489	3,2
MAB-16-0484	21,9
MAB-16-0464	3,0
MAB-16-0267	3,4
MAB-16-0406	6,6
MAB-16-0400	5,8
CP-870-IgG1-LALA	14,5

(57) **Abstract:** The present invention relates to humanized monoclonal antibodies or antigen-binding fragments thereof that specifically bind to human CD40 receptor and induce CD40 signaling independent of Fey mediated CD40 receptor crosslinking. The antibodies of the present invention bind to a CD40 epitope that overlaps with the epitope of the CD40 ligand and can activate human APCs. The present invention also provides for compositions comprising said antibodies and uses for the antibodies and compositions in the treatment of patients suffering from cancer.



WO 2019/057792 A1